SCHEMBL879877

SCHEMBL879877

COC(=O)c1cccc(CCCC(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.68
CYP4A11 Q02928 3/20 0.68
LOXL2 Q9Y4K0 1/20 0.57
MRGPRX4 Q96LA9 4/20 0.55
SLC7A5 Q01650 1/20 0.50
PARP1 P09874 1/20 0.47
FOLH1 Q04609 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
DHODH Q02127 1/20 0.46
HIF1A Q16665 1/20 0.45
KCNH2 Q12809 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70173 0.83 CYP4F2 (0.83) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL5663990 0.82 CYP4A11 (0.91) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL10606812 0.82 CYP4A11 (0.75) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL1792728 0.82 CYP4A11 (0.75) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL850937 0.82 FOLH1 (0.53) MRGPRX4FOLH1ALDH1A1HIF1A
SCHEMBL10144968 0.82 LOXL2 (0.64) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL880015 0.82 CYP4A11 (0.66) CYP4F2CYP4A11LOXL2ALDH1A1HPGD
SCHEMBL10291095 0.81 CYP4F2 (0.67) CYP4F2CYP4A11ALDH1A1HPGDMAPT
SCHEMBL18540811 0.81 CYP4A11 (1.00) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5
SCHEMBL8921794 0.81 CYP4A11 (0.73) CYP4F2CYP4A11LOXL2MRGPRX4SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 CYP4F2 2161/4885CYP4A11 328/4885LOXL2 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.